Clinical TrialsPreliminary data from the breast cancer vaccine study are encouraging, with over 70% of patients showing a protocol-defined immune response.
Intellectual PropertyThe United States Patent and Trademark Office is set to issue a patent that covers Anixa Biosciences' breast cancer vaccine technology, extending intellectual property protection into the mid-2040s.
PartnershipsAnixa entered into a letter of intent with VERDI Solutions for its personalized, off-the-shelf, cancer vaccine platform, with plans to initiate US clinical studies.